Affiliation:
1. L.I. Medved’s Research Center of Preventive Toxicology, Food and Chemical Safety, Ministry of Health, Ukraine (State Enterprise), Kyiv, Ukraine
2. Shupyk National University of Health Care of Ukraine, Kyiv, Ukraine
3. CNE "Kyiv City Clinical Hospital of Emergency Medical Care", Kyiv, Ukraine
Abstract
Introduction. In the conditions of the spread of powerful synthetic opioids, the traditionally recommended doses of Naloxone may be insufficient; instead, a significant increase in the dose of Naloxone leads to side effects, which in turn creates a threat to life.
Aim. Analysis of the results of own research and scientific information regarding the use of Naloxone in the treatment of synthetic opioids poisoning and the development of alternative antidotes.
Materials and Methods. The medical data of 174 patients treated with the diagnosis: "Acute narcotic poisoning" (ICD-10:Т40.0-Т40.3) were studied. Laboratory studies were carried out by the method of immunochromatographic analysis and chromatographymass spectrometry. Statistical data processing was performed using the IBM SPSS Statistics 29.0.0.0 program, using Spearman's rank correlation analysis (r), with p ≤ 0.05.
Results. Among patients who received Naloxone, the best dynamics according to the Glasgow coma scale at the 4th and 6th hours of observation were those who received 2-6 mg of Naloxone. A significant part of patients (76 cases, 43.68 %) required repeated administration of Naloxone due to the renarcotization, in such cases a direct correlation was established with the occurrence of undesirable clinical effects (r = 0.864, p = 0.05). A direct relationship between an increase in the dose of Naloxone and the development of arterial hypertension (r = 0.945, p = 0.01), convulsions (r = 0.887, p = 0.01), withdrawal and pain syndrome (r = 0.881, p = 0.01). In general, the occurrence of clinical effects was correlated with an increase in the dose of Naloxone (R2 = 0.92), however, the rank correlation analysis did not confirm the relationship between the dose of Naloxone and the development of pulmonary edema (r = 0.938, p > 0.05), cardiac arrhythmia (r= 0.598, p > 0.05), cardiac arrest (r= -0.146, p > 0.05).
Conclusions. The use of high doses of Naloxone does not solve the problem of prevention of opioid overdoses and their effective treatment. The development of new models of antidotes to opioids using сovalent Naloxone nanoparticles, serotonin 5-HT1A agonists, Fentanyl-binding Cyclodextrin scaffolds, specific vaccines, etc. is considered promising.
Keywords: opioids, antidotes, Naloxone, Fentanyl.
Publisher
L. I. Medved Research Center of Preventive Toxicology, Food and Chemical Safety
Reference18 articles.
1. European Monitoring Center for Drugs and Drug Addiction (EMCDDA). European Drug Report 2021: Trends and Developments. URL:https://www.emcdda.europa.eu/publications/edr/trends-developments/2021_en.
2. Looking back on 25 years of annual reporting on the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, 2020. Electronic resource. Available online:https://www.emcdda.europa.eu/publications/brochures/25-years-annual-reporting_en. doi:10.2810/199193.
3. Wilson N, Kariisa M, Seth P, Smith H. 4th, Davis N.L. Drug and Opioid-Involved Overdose Deaths – United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297. doi:10.15585/mmwr.mm6911a4.
4. Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, Doe-Simkins M, Walley AY, Marshall BDL, Bratberg J, Green TC. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022 Mar; 7(3):e210-e218. doi:10.1016/S2468-2667(21)00304-2.
5. Shaw LV, Moe J, Purssell R, Buxton JA, Godwin J, Doyle-Waters MM, Brasher PMA, Hau JP, Curran J, Hohl CM. Naloxone interventions in opioid overdoses: a systematic review protocol. Syst Rev. 2019 Jun 11;8(1):138. doi:10.1186/s13643-019-1048-y.